Kaddoussi Rania, Rejeb Hadhemi, Kalai Amine, Zaara Eya, Rouetbi Naceur, Salah Frih Zohra Ben, Zmijewski Piotr, Ben Saad Helmi
Department of Pneumology, Fattouma Bourguiba Hospital, Monastir, Tunisia.
Ibn Nafiss department of Pneumology, Abdelrahman Mami hospital, Ariana, Tunisia.
Biol Sport. 2024 Oct;41(4):197-217. doi: 10.5114/biolsport.2024.139072. Epub 2024 Apr 25.
There is a lack of randomized clinical trials (RCTs) exploring the outcomes of cardiopulmonary rehabilitation programmes (CPRPs) on submaximal aerobic capacity of long COVID-19 patients (LC19Ps). This RCT aimed to evaluate the effect of an ambulatory CPRP on the 6-min walk test (6MWT) data (main outcome: 6-min walk distance (6MWD)) of LC19Ps. Conducted as a single-blinded RCT, the study included Tunisian LC19Ps with persistent dyspnoea (i.e. modified medical research council (mMRC) level ≥2) at least three months postdiagnosis. LC19Ps were randomly assigned to the intervention (IG, n = 20) or control (CG, n = 10) groups. Pre- and post-CPRP evaluations included dyspnoea assessments (Borg and mMRC scales), anthropometric data, spirometry, and 6MWT. The CPRP (i.e. 18 sessions over six weeks) encompassed warm-up, aerobic training, resistance training, respiratory exercises, and therapeutic education. The CPRP significantly improved i) dyspnoea, i.e. IG exhibited larger reductions compared to the CG in Borg (-3.5 ± 2.0 vs. -1.3 ± 1.5) and mMRC (-1.5 ± 0.8 vs. -0.1 ± 0.3) scales, and ii) 6MWD, i.e. IG demonstrated larger improvements compared to the CG in 6MWD (m, %) (168 ± 99 vs. 5 ± 45 m, 28 ± 8 vs. 1 ± 8%, respectively), and resting heart rate (bpm, % maximal predicted heart rate) (-9 ± 9 vs. 1 ± 7 bpm; -5 ± 6 vs. 0 ± 4%, respectively), with small effect sizes. In the IG, the 1.5-point decrease in mMRC and the 168 m increase in 6MWD exceeded the recommended minimal clinical important differences of 1 point and 30 m, respectively. CPRP appears to be effective in enhancing the submaximal exercise capacity of LC19Ps, particularly in improving 6MWD, dyspnoea, and resting heart rate. RCT registration: www.pactr.org; PACTR202303849880222.
目前缺乏探索心肺康复计划(CPRP)对新冠后长期症状患者(LC19Ps)次最大有氧运动能力影响的随机临床试验(RCT)。本RCT旨在评估门诊CPRP对LC19Ps的6分钟步行试验(6MWT)数据(主要结局:6分钟步行距离(6MWD))的影响。该研究作为一项单盲RCT进行,纳入了诊断后至少三个月仍有持续性呼吸困难(即改良医学研究委员会(mMRC)分级≥2级)的突尼斯LC19Ps患者。LC19Ps被随机分为干预组(IG,n = 20)或对照组(CG,n = 10)。CPRP前后的评估包括呼吸困难评估(Borg量表和mMRC量表)、人体测量数据、肺功能测定和6MWT。CPRP(即六周内进行18次训练)包括热身、有氧训练、抗阻训练、呼吸练习和治疗教育。CPRP显著改善了:i)呼吸困难,即IG组在Borg量表(-3.5±2.0 vs. -1.3±1.5)和mMRC量表(-1.5±0.8 vs. -0.1±0.3)上的下降幅度大于CG组;ii)6MWD,即IG组在6MWD(米,%)方面的改善幅度大于CG组(分别为168±99 vs. 5±45米,28±8 vs. 1±8%),以及静息心率(次/分钟,最大预测心率的%)(分别为-9±9 vs. 1±7次/分钟;-5±6 vs. 0±4%),效应量较小。在IG组中,mMRC下降1.5分和6MWD增加168米分别超过了推荐的最小临床重要差异1分和30米。CPRP似乎能有效提高LC19Ps的次最大运动能力,尤其是在改善6MWD、呼吸困难和静息心率方面。RCT注册:www.pactr.org;PACTR202303849880222。